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Disturbances of heme synthesis, and thereby
porphyrin metabolism and excretion, are well
known in patients with chronic liver disease of
various aetiology such as heavy metal exposure,
liver cirrhosis and chronic hepatitis (Doss &
Martini, 1977). Also in bone marrow diseases such
as leukaemia, pernicious and haemolytic anaemias
such disturbances have been reported. The usual
findings in liver and bone marrow diseases have
been that of an asymptomatic patient with isolated
coproporphyrinuria. A number of case reports have
been published on patients with liver tumours,
benign as well as malignant including liver
metastases, coincident with symptomatic hepatic
porphyria clinically manifest as porphyria cutanea
tarda (PCT) (Thompson et al., 1970; Waddington,
1972). In some of these cases a reduced uro-
porphyrinogen decarboxylase activity has been
detected and this enzyme defect has been regarded
as a paraneoplastic phenomenon caused by liver
damage (Doss & Martini, 1977). An increased risk
of hepatocellular cancer (HCC) has been reported
in patients with PCT (Berman & Braun, 1962;
Kordac, 1972; Salata et al., 1985). Liver cancer in
PCT patients has almost invariably developed in
cirrhotic livers, cirrhosis thought to be the
prerequisite for carcinogenesis. Agents associated
with an increased risk of HCC such as alcohol,
steroid hormones and aflatoxin are potent
porphyrinogenic substances (Kappas & Granick,
1968; Sherlock, 1981; Zawirska & Bednarz,
1981). In animal experimental models of porphyria
hexachlorobenzene (HCB) has been widely used
(Koss et al., 1983; Wainstok de Calmanovici et al.,
1984). HCB is also a liver carcinogen in several
animal species (Cabral et al., 1977; 1979; Smith &
Cabral, 1980).
Recently an association between porphyria acuta
intermittens (PAI) and HCC has been reported
(Lithner & Wetterberg, 1984; Hardell et al., 1984;
Kaupinnen & Mustajoki, Unpublished). In our case
control study 3 cases of PAI were identified among
the 83 patients with HCC versus none among the
200 controls (Hardell et al., 1984). PAI is an inborn
error of metabolism inherited as a dominant trait
and characterized by a reduced activity of the rate-
limiting enzyme in heme synthesis, uroporphyrino-
gen-l-synthetase. The disease is often manifested at
the age of puberty. The clinical picture of an acute
attack is characterized by abdominal pain,
neurological symptoms, changes in electrolytes and
marked increase in the excretion of two precursors
in heme synthesis, amino levulinic acid (ALA) and
porphobilinogen (PBG). PAI is a rare disease
worldwide and our region is actually' one of the
high incidence areas with an estimated prevalence
of 1 case per 1000 inhabitants (Waldenstr6m, 1969).
A mapping of the pedigrees of 2 families has been
performed and is presented in Figures la,b.
In total 5 cases of HCC in persons with PAI
were identified in these 2 families. The age at
diagnosis was: 66, 67, 69, 69 and 70 years. The male
in the first generation in family 1 was the carrier of
FAMILY 1
a i l
FAMILY 2
b
O Female
O3 Female with PAI
* Female with PAI and HCC
O Male
O Male with PAI
* Male with PAI and HCC
Figure la,b Pedigrees of 2 families with porphyria
acuta intermittens. PAI= porphyria acuta intermittens;
HCC =hepatocellular cancer.
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the trait. He died at the age of 77 from broncho-
pneumonia, autopsy was not performed. In family 1
there were 4 siblings with PAI in the second
generation of whom 1 died at the age of 43 in an
acute attack of porphyria and the other three
developed HCC. In family 2 the female in the first
generation was the carrier of the trait. She died at
the age of 46 of uraemia. Of the 5 siblings in the
second generation 3 had PAI of which 2 developed
HCC. The third person with PAI died at the age
of 46 with an extrahepatic cholangiocellular
carcinoma. No further cases of HCC have been
found in the 2 families but the living carriers of the
trait are still fairly young. In all cases of HCC in
this pedigree mapping, as well as in the case control
study (Hardell et al., 1984), diagnoses were based
on histopathological examination of biopsy and
autopsy material.
Various hypotheses can be postulated for the
accumulation of HCC in families with PAI. The
genetic locus for uroporphyrinogen-1-synthetase is
located to the long arm of chromosome 11 (Meisler
et al., 1980). This point mutation could be associated
with an oncogene responsible for the high risk of
HCC development in these persons. No data are
available regarding this, however. Another theory is
that porphyrins are carcinogenic per se. This
hypothesis can be supported by:
1. Porphyrins have photochemical cytotoxic
properties and upon illumination form highly
reactive oxygen radicals (Weishaupt et al., 1976;
Brault et al., 1985). This effect has been used to
treat cutaneous and subcutaneous metastases of
various cancers in humans (Wile et al., 1984).
2. In a recent study of HCB-induced hepato-
carcinogenesis rats were fed HCB in diet for 90
weeks (Smith et al., 1985). Both sexes showed a
decrease in uroporphyrinogen decarboxylase
activity. Massive porphyria developed in females
but not in males. After 90 weeks of HCB
treatment 100% of the female rats developed
multiple liver tumours versus only 16% of the
male rats. Analysis of HCB content in liver
tissue showed no differences between males and
females. These findings indicate that HCB exerts
its hepatocarcinogenic action via porphyrins.
3. In a study of patients with PCT 17 out of 342
patients followed in the years 1954-69 developed
HCC. Another group of 367 PCT patients were
treated with chloroquine 250mg p.o. twice a
week and followed in the years 1969-83. Of
these only 3 developed HCC. The cutaneous
symptoms as well as the urine excretion of
uroporphyrin and coproporphyrin were
significantly lowered in the chloroquine group
(Kordac et al., unpublished).
4. In a study of porphyrin metabolism a group of
patients with liver cirrhosis and another group
with liver cirrhosis and HCC were compared
with healthy controls (Udagawa et al., 1984). A
significant increase of uroporphyrin and
coproporphyrin excretion in urine was found in
both patient groups. Furthermore HCC patients
showed significantly higher excretion of
porphyrins compared with patients with only
liver cirrhosis. No correlation between porphyrin
excretion and liver function tests was found.
The increased risk for HCC in persons with hepatic
porphyrias and results from experimental
investigations have initiated further studies on
porphyrins in hepatocarcinogenesis.
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